Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome

Enrico Carmina, Frank Gonzalez, Lilly Chang, Rogerio A. Lobo

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods: Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results: Twenty-one (70%) of the women with PCOS had elevations of DHEA sulfate, and 16 (53%) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37%) had elevated values of DHEA sulfate. Four of 16 women had reductions in 11β-hydroxyandrostenedione. Only those with elevated baseline DHEA sulfate levels had reductions after GnRH-A therapy. The reduction of DHEA sulfate with GnRH-A correlated with the reduction in androstenedione. Of the subjects who had reductions in DHEA sulfate with GnRH-A therapy, there was a blunted response of DHEA to ACTH after treatment. Conclusion: Our findings suggest that the ovary may influence the prevalence and magnitude of adrenal androgen excess in PCOS.

Original languageEnglish (US)
Pages (from-to)971-976
Number of pages6
JournalObstetrics and Gynecology
Volume85
Issue number6
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Dehydroepiandrosterone Sulfate
Polycystic Ovary Syndrome
Gonadotropin-Releasing Hormone
Androgens
Adrenocorticotropic Hormone
Therapeutics
Dehydroepiandrosterone
Androstenedione
Ovary
Reference Values
Serum
11-hydroxyandrostenedione

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. / Carmina, Enrico; Gonzalez, Frank; Chang, Lilly; Lobo, Rogerio A.

In: Obstetrics and Gynecology, Vol. 85, No. 6, 1995, p. 971-976.

Research output: Contribution to journalArticle

Carmina, Enrico ; Gonzalez, Frank ; Chang, Lilly ; Lobo, Rogerio A. / Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. In: Obstetrics and Gynecology. 1995 ; Vol. 85, No. 6. pp. 971-976.
@article{b8f15fa0fc8c481ea70301838f49b734,
title = "Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome",
abstract = "Objective: To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods: Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results: Twenty-one (70{\%}) of the women with PCOS had elevations of DHEA sulfate, and 16 (53{\%}) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37{\%}) had elevated values of DHEA sulfate. Four of 16 women had reductions in 11β-hydroxyandrostenedione. Only those with elevated baseline DHEA sulfate levels had reductions after GnRH-A therapy. The reduction of DHEA sulfate with GnRH-A correlated with the reduction in androstenedione. Of the subjects who had reductions in DHEA sulfate with GnRH-A therapy, there was a blunted response of DHEA to ACTH after treatment. Conclusion: Our findings suggest that the ovary may influence the prevalence and magnitude of adrenal androgen excess in PCOS.",
author = "Enrico Carmina and Frank Gonzalez and Lilly Chang and Lobo, {Rogerio A.}",
year = "1995",
doi = "10.1016/0029-7844(95)00065-Y",
language = "English (US)",
volume = "85",
pages = "971--976",
journal = "Obstetrics and Gynecology",
issn = "0029-7844",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome

AU - Carmina, Enrico

AU - Gonzalez, Frank

AU - Chang, Lilly

AU - Lobo, Rogerio A.

PY - 1995

Y1 - 1995

N2 - Objective: To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods: Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results: Twenty-one (70%) of the women with PCOS had elevations of DHEA sulfate, and 16 (53%) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37%) had elevated values of DHEA sulfate. Four of 16 women had reductions in 11β-hydroxyandrostenedione. Only those with elevated baseline DHEA sulfate levels had reductions after GnRH-A therapy. The reduction of DHEA sulfate with GnRH-A correlated with the reduction in androstenedione. Of the subjects who had reductions in DHEA sulfate with GnRH-A therapy, there was a blunted response of DHEA to ACTH after treatment. Conclusion: Our findings suggest that the ovary may influence the prevalence and magnitude of adrenal androgen excess in PCOS.

AB - Objective: To reevaluate the clinical significance of elevations of adrenal androgens in polycystic ovary syndrome (PCOS). Methods: Thirty women with PCOS and ten ovulatory controls were evaluated. Serum dehydroepiandrosterone (DHEA) sulfate and 11β-hydroxyandrostenedione were measured before and after 3 and 6 months of GnRH agonist (GnRH-A) therapy. All controls and 15 women with PCOS received intravenous ACTH before and after GnRH-A therapy. Results: Twenty-one (70%) of the women with PCOS had elevations of DHEA sulfate, and 16 (53%) had elevations in 11/3-hydroxyandrostenedione. Only two women with PCOS had normal values of both adrenal androgens. After GnRH-A therapy, only 11 subjects (37%) had elevated values of DHEA sulfate. Four of 16 women had reductions in 11β-hydroxyandrostenedione. Only those with elevated baseline DHEA sulfate levels had reductions after GnRH-A therapy. The reduction of DHEA sulfate with GnRH-A correlated with the reduction in androstenedione. Of the subjects who had reductions in DHEA sulfate with GnRH-A therapy, there was a blunted response of DHEA to ACTH after treatment. Conclusion: Our findings suggest that the ovary may influence the prevalence and magnitude of adrenal androgen excess in PCOS.

UR - http://www.scopus.com/inward/record.url?scp=0029015550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029015550&partnerID=8YFLogxK

U2 - 10.1016/0029-7844(95)00065-Y

DO - 10.1016/0029-7844(95)00065-Y

M3 - Article

VL - 85

SP - 971

EP - 976

JO - Obstetrics and Gynecology

JF - Obstetrics and Gynecology

SN - 0029-7844

IS - 6

ER -